Doxepin vs Imipramine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Tricyclic Antidepressant

Doxepin

Brand: Doxepin

First FDA approval: 1986-05-13

Tricyclic Antidepressant

Imipramine

First FDA approval: 2010-04-16

Lowest NADACAcquisition cost floor across all NDCs

$0.078Per unit

$0.083Per unit

Average NADACAcross all dosage forms and strengths

$0.539Up to $6.70

$0.914Up to $3.78

Generic manufacturersActive ANDA holders — FDA Orange Book

25102 total ANDAs filed

722 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$99.4MFull year

$6.9MFull year

Part D claims (CY24)Total fills, all strengths

1.9M521K beneficiaries

301K76K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$52Per claim, all NDCs

$23Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

665Substantial friction

143Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

2Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes25 manufacturers

Yes7 manufacturers